Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 28754483

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2017 Sep
First author
Pujade-Lauraine E

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2017 Sep;18(9):1151-1152. doi: 10.1016/S1470-2045(17)30567-3.
    note
    Source null
    related pmid
    28754484
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2017 Oct;14(10):586-587. doi: 10.1038/nrclinonc.2017.130.
    note
    Source null
    related pmid
    28812596
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2017 Sep;18(9):e510. doi: 10.1016/S1470-2045(17)30639-3.
    note
    Source null
    related pmid
    28884698
    relationship
    Erratum in

Authors and identifiers

  1. name
    Pujade-Lauraine E
    type
    Author
  2. name
    Ledermann JA
    type
    Author
  3. name
    Selle F
    type
    Author
  4. name
    Gebski V
    type
    Author
  5. name
    Penson RT
    type
    Author
  6. name
    Oza AM
    type
    Author
  7. name
    Korach J
    type
    Author
  8. name
    Huzarski T
    type
    Author
  9. name
    Poveda A
    type
    Author
  10. name
    Pignata S
    type
    Author
  11. name
    Friedlander M
    type
    Author
  12. name
    Colombo N
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Pujade-Lauraine E
    type
    Author
  2. name
    Ledermann JA
    type
    Author
  3. name
    Selle F
    type
    Author
  4. name
    Gebski V
    type
    Author
  5. name
    Penson RT
    type
    Author
  6. name
    Oza AM
    type
    Author
  7. name
    Korach J
    type
    Author
  8. name
    Huzarski T
    type
    Author
  9. name
    Poveda A
    type
    Author
  10. name
    Pignata S
    type
    Author
  11. name
    Friedlander M
    type
    Author
  12. name
    Colombo N
    type
    Author
bibliography ids
  1. nci-bib-62a76974ed7c9e8dd09a70f0
book metadata
content sha256
9e1effb9e6e0e8a4f26ea63bc0314ad69592bf4d6e6cbdff746201eaf3bd7148
document type
citation
dois
  1. 10.1016/S1470-2045(17)30469-2
electronic publication date
display
2017 Jul 25
precision
day
year
2017
evidence scope
bibliographic_metadata_only
id
pubmed:28754483
immutable id
pubmed:28754483@9e1effb9e6e0e8a4f26ea63bc0314ad69592bf4d6e6cbdff746201eaf3bd7148
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
9
name
The Lancet. Oncology
nlm unique id
100957246
pages
1274-1284
volume
18
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2017 Sep;18(9):1151-1152. doi: 10.1016/S1470-2045(17)30567-3.
    note
    Source null
    related pmid
    28754484
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2017 Oct;14(10):586-587. doi: 10.1038/nrclinonc.2017.130.
    note
    Source null
    related pmid
    28812596
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2017 Sep;18(9):e510. doi: 10.1016/S1470-2045(17)30639-3.
    note
    Source null
    related pmid
    28884698
    relationship
    Erratum in
outcomes validated
false
pmid
28754483
provenance
batch id
fb25b16edcb1373b70c1
provider
NCBI PubMed ESummary
record sha256
d558eb7c0ee71477eab52135df4ce573a3334e79b6d3cbc3ff6925ea8fb094ed
response sha256
182c99bf1974b58308315b66aa28d31c61e8fc31cf3de4cadb0340a4f6734c52
retrieved at
2026-09-09T23:47:28.490065+00:00
publication date
display
2017 Sep
precision
month
year
2017
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/28754483/
title
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.

Preserved source evidence · Not medical advice